SHARIAH / WAM In a high-level meeting chaired by Sheikha Bodour Al Qasimi, the Board ...
Read More »Pfizer’s Biohaven deal may open era of ‘pharma M&A’
With biotech stocks in the dumps, investors have been hoping for deals to revive the sector, but lately merger-and-acquisition activity has been anemic. Finally, Pfizer announced it will buy Biohaven Pharmaceutical Holding Company Ltd, a nine-year-old company that makes treatments for migraines, for $11.6 billion. The deal, which gives Pfizer an oral drug already on the market and a nasal ...
Read More »